Literature DB >> 34244606

The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer.

Pei Yu1, Xiong Zhu2, Jia-Le Zhu1, Yu-Bao Han1, Hao Zhang1, Xiang Zhou3, Lei Yang1, Yuan-Zheng Xia1, Chao Zhang4, Ling-Yi Kong5.   

Abstract

Vasculogenic mimicry (VM) formation, which participates in the process of neovascularization, is highly activated in p53-mutated triple-negative breast cancer (TNBC). Here, we show that Chk2 is negatively correlated with VM formation in p53-mutated TNBC. Its activation by DNA-damaging agents such as cisplatin, etoposide, and DPT reduces VM formation. Mechanistically, the Chk2-PKM2 axis plays an important role in the inhibition of VM formation at the level of metabolic regulation. Chk2 promotes the Chk2-PKM2 interaction through the Chk2 SCD (SQ/TQ cluster domain) and the PKM2 C domain. Furthermore, Chk2 promotes the nuclear export of PKM2 by phosphorylating PKM2 at Ser100. P-PKM2 S100 reduces VM formation by decreasing glucose flux, and the PKM2 S100A mutation abolishes the inhibition of glucose flux and VM formation induced by Chk2 activation. Overall, this study proposes a novel strategy of VM suppression through Chk2 induction, which prevents PKM2-mediated glucose flux in p53-mutated TNBC.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34244606     DOI: 10.1038/s41388-021-01933-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

1.  A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis.

Authors:  Elvin Wagenblast; Mar Soto; Sara Gutiérrez-Ángel; Christina A Hartl; Annika L Gable; Ashley R Maceli; Nicolas Erard; Alissa M Williams; Sun Y Kim; Steffen Dickopf; J Chuck Harrell; Andrew D Smith; Charles M Perou; John E Wilkinson; Gregory J Hannon; Simon R V Knott
Journal:  Nature       Date:  2015-04-08       Impact factor: 49.962

2.  CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer.

Authors:  T J Liu; B C Sun; X L Zhao; X M Zhao; T Sun; Q Gu; Z Yao; X Y Dong; N Zhao; N Liu
Journal:  Oncogene       Date:  2012-04-02       Impact factor: 9.867

3.  Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.

Authors:  Kang Liu; Fang-Tsyr Lin; Joshua D Graves; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

4.  Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Authors:  Fotini Vogiatzi; Dominique T Brandt; Jean Schneikert; Jeannette Fuchs; Katharina Grikscheit; Michael Wanzel; Evangelos Pavlakis; Joël P Charles; Oleg Timofeev; Andrea Nist; Marco Mernberger; Eva J Kantelhardt; Udo Siebolts; Frank Bartel; Ralf Jacob; Ariane Rath; Roland Moll; Robert Grosse; Thorsten Stiewe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

Review 5.  Mutant p53 on the Path to Metastasis.

Authors:  Qiaosi Tang; Zhenyi Su; Wei Gu; Anil K Rustgi
Journal:  Trends Cancer       Date:  2019-12-16

6.  ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells.

Authors:  E M Langer; N D Kendsersky; C J Daniel; G M Kuziel; C Pelz; K M Murphy; M R Capecchi; R C Sears
Journal:  Oncogene       Date:  2017-10-30       Impact factor: 9.867

7.  TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Authors:  Utpal K Mukhopadhyay; Chetan C Oturkar; Christina Adams; Nadi Wickramasekera; Sanjay Bansal; Rajesh Medisetty; Austin Miller; Wendy M Swetzig; Laxmi Silwal-Pandit; Anne-Lise Børresen-Dale; Chad J Creighton; Jun Hyoung Park; Santhi D Konduri; Alka Mukhopadhyay; Alexander Caradori; Angela Omilian; Wiam Bshara; Benny Abraham Kaipparettu; Gokul M Das
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 11.816

Review 8.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

9.  Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.

Authors:  P A J Muller; A G Trinidad; P Timpson; J P Morton; S Zanivan; P V E van den Berghe; C Nixon; S A Karim; P T Caswell; J E Noll; C R Coffill; D P Lane; O J Sansom; P M Neilsen; J C Norman; K H Vousden
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more
  3 in total

1.  Orchestrated expression of vasculogenic mimicry and laminin-5γ2 is an independent prognostic marker in oral squamous cell carcinoma.

Authors:  Depanwita Saha; Debarpan Mitra; Neyaz Alam; Sagar Sen; Saunak Mitra Mustafi; Syamsundar Mandal; Biswanath Majumder; Nabendu Murmu
Journal:  Int J Exp Pathol       Date:  2022-02-16       Impact factor: 1.925

2.  Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.

Authors:  Ji Sun Lee; Yunmoon Oh; Jin-Sol Lee; Jae Hyeon Park; Joo-Kyung Shin; Joo-Hee Han; Hyung Sik Kim; Sungpil Yoon
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

Review 3.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.